PT-141 (Bremelanotide)
PeptideThe medical score is higher, as two Phase III RCTs and FDA approval [s5, s7] establish a solid clinical evidence base. The community rates the substance more critically due to frequent nausea, unpredictable efficacy, and the requirement for injection [c1, c2, c3].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
PT-141 is the only centrally acting peptide with FDA approval (2019) for hypoactive sexual desire disorder in premenopausal women — statistically solid, but with only moderate effect sizes in clinical trials. In men with erectile dysfunction, a Phase II RCT showed 34% responders vs. 9% on placebo, promising but not approval-worthy. The biggest real-world issue: up to 40% of trial participants experienced nausea, and the requirement for a subcutaneous injection shortly before sex is a practical and mood-dampening barrier for many users. Outside the US, PT-141 has no regulatory approval; sourcing it through unregulated channels carries both legal and quality risks.
Description
Cyclic melanocortin peptide for treatment of Hypoactive Sexual Desire Disorder (HSDD) – acts centrally via MC3R/MC4R, not vascularly [s1, s2].
PT-141 (bremelanotide) is a synthetic, cyclic heptapeptide and agonist at melanocortin receptors (MC3R, MC4R) in the central nervous system. It was originally developed as a derivative of Melanotan II and its sexually stimulating effects were discovered incidentally during studies on sunless tanning [s6]. In 2019, the FDA granted approval under the trade name Vyleesi® as a subcutaneous injection (1.75 mg) for the treatment of generalized, acquired Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women [s7]. In contrast to PDE-5 inhibitors such as sildenafil, which act peripherally via vasodilation, PT-141 exerts its effects directly in the brain via melanocortinergic signaling pathways associated with sexual motivation, desire, and arousal [s1, s2, s3]. This makes it potentially relevant in sexual dysfunction with a predominantly neurobiological or psychological etiology [s4]. In two Phase III RCTs involving premenopausal women, bremelanotide demonstrated statistically significant improvements in sexual desire and personal distress versus placebo [s5]. In men with erectile dysfunction – particularly those with inadequate response to sildenafil – Phase II data are available showing efficacy in approximately 34% of participants [s4]. The most common adverse effects are nausea, vomiting, headache, flushing, and transient blood pressure elevation [s8, s9]. Focal hyperpigmentation was observed in approximately 1% of female users [s9]. In Europe (EMA), bremelanotide has not been approved for any indication; Gedeon Richter evaluated Phase III data following FDA approval, but no EU authorization has been granted [s10].
Legal Status (DE)
In the United States, bremelanotide has been approved as a prescription drug (Vyleesi®) since 2019 [s7]. In Germany, Austria, and Switzerland, no EMA approval exists; the product is classified as an unauthorized medicinal product under the German Medicines Act (AMG § 2) and may not be dispensed or imported without a medical prescription. Purchase through unregulated online sources is legally problematic and associated with quality and safety risks [s8, s10, s11].
Mechanism of Action
PT-141 binds with high affinity to melanocortin receptors MC3R and MC4R, which are predominantly expressed in hypothalamic nuclei [s1, s2]. Activation of these receptors stimulates adenylyl cyclase and increases intracellular cAMP levels, modulating neuronal excitability in centers controlling sexual behavior [s1, s3]. Melanocortinergic activation engages dopaminergic pathways and triggers nitric oxide (NO) release via central signaling mechanisms [s3]. These central mechanisms increase sexual motivation and desire independently of peripheral vascular function [s2, s4]. Neurons in the same hypothalamic region are connected to the corpus cavernosum via transneuronal pathways, which explains why PT-141 can also mediate erectogenic effects [s1]. Since the mechanism of action does not depend on adequate vascular function, PT-141 may be effective in patients who do not respond to PDE-5 inhibitors [s4]. Inhibition of inhibitory signals and amplification of excitatory melanocortinergic signals within the balance of the sexual response system account for the clinically observed effects [s2]. Pharmacokinetics: Following subcutaneous injection, bioavailability is nearly 100%; peak plasma concentration is reached at approximately 1 hour (range 0.5–1 h). Plasma protein binding is 21%. Half-life is approximately 2.7 hours [s6]. The intranasal formulation was not further developed due to excessively variable bioavailability and more pronounced blood pressure effects [s6, s9].
Dosing
HSDD bei Frauen (FDA-zugelassene Indikation)
- Dose
- 1.75 mg subcutaneous (auto-injector)
- Frequency
- Bei Bedarf, max. 1× pro 24 Stunden
- Route
- injektion-subkutan
- Duration
- Bedarfsweise, keine Dauertherapie
- Timing
- Approx. 45 minutes before planned sexual activity
- With food
- optional
Off-label bei erektiler Dysfunktion (Männer, nicht zugelassen)
- Dose
- 1.0–2.0 mg subcutaneous (research context)
- Frequency
- Bei Bedarf, max. 1× pro 24 Stunden
- Route
- injektion-subkutan
- Duration
- Bedarfsweise
- Timing
- Approx. 60 minutes before planned sexual activity
- With food
- optional
Titrationseinstieg (Community-Protokoll, nicht FDA-geprüft)
- Dose
- 0.5–0.75 mg subcutaneously
- Frequency
- Einmalig zur Verträglichkeitsprüfung
- Route
- injektion-subkutan
- Duration
- Einmalig
- Timing
- Approx. 60 minutes before planned activity
- With food
- optional
According to the FDA prescribing information, no more than one dose (1.75 mg) should be administered within a 24-hour period [s7]. Higher doses increase the risk of nausea, vomiting, and more pronounced blood pressure elevations [s9].
The intranasal formulation is no longer in development due to variable bioavailability and more pronounced cardiovascular effects [s6]. PT-141 should not be used in combination with indomethacin or naltrexone, as clinically relevant pharmacokinetic interactions have been documented [s8]. The substance is not approved in Germany; procurement outside of a medical prescription is legally problematic [s10, s11].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Übelkeit Most common adverse effect in phase III trials; dose-dependent, reported in up to 40% of users [s5, s9]. | häufig | moderat |
| Erbrechen Less frequent than nausea, but also dose-dependent; documented in clinical trials [s9]. | gelegentlich | moderat |
| Kopfschmerzen Reported in clinical trials; typically transient [s9, s8]. | gelegentlich | leicht |
| Flush (Hautrötung, Hitzegefühl) Melanocortinergic activation can lead to peripheral vasodilation and flushing [s8, s9]. | gelegentlich | leicht |
| Vorübergehende Blutdruckerhöhung und Herzfrequenzabfall Transient systolic blood pressure elevations following injection have been documented; may impair the efficacy of antihypertensive agents [s7, s8]. | häufig | moderat |
| Lokale Reaktionen an der Injektionsstelle (Schmerz, Rötung) Typical injection-site reactions; documented in studies [s7]. | gelegentlich | leicht |
| Fokale Hyperpigmentierung (Gesicht, Zahnfleisch, Brust) Observed in approximately 1% of users with repeated administration; reversible upon discontinuation [s9, s7]. | selten | leicht |
| Spontane Erektionen (Männer, off-label) May occur as an unwanted effect, particularly at higher doses; described in community reports [c2, c4]. | gelegentlich | leicht |
Contraindications
PT-141 causes transient blood pressure elevations; pre-existing uncontrolled hypertension carries an increased risk of hypertensive crises [s7, s8].
Contraindicated in patients with cardiovascular disease per FDA prescribing information, due to risks of transiently elevated blood pressure [s7].
Animal studies demonstrate potential fetal harm with subcutaneous administration; use during pregnancy is contraindicated [s7].
Insufficient safety data; use not recommended [s7].
Bremelanotide reduces plasma concentrations of naltrexone; concomitant use is not recommended per FDA label [s8].
Bremelanotide reduces plasma concentrations of indomethacin; concomitant use is not recommended per FDA label [s8].
Interactions
Synergistic
Combination shows stronger erectile effect than sildenafil alone in men with inadequate sildenafil response; however, increased risk of additive hypotension and enhanced erections up to the point of pain [s4, c2].
Kisspeptin-10 and PT-141 act on sexual function via distinct pathways — kisspeptin via the GPR54/GnRH axis, PT-141 via MC3R/MC4R. A combination could produce complementary effects on libido and arousal without direct receptor competition.
PT-141 as a non-hormonal peptide can be used adjunctively with testosterone or hormone replacement therapy. Testosterone supports the hormonal foundation, while PT-141 acutely enhances central arousal.
The combination of PT-141 with tadalafil may act synergistically, as PT-141 centrally enhances arousal and tadalafil peripherally increases blood flow. Clinical observations recommend caution, however, due to additive hypotension.
Caution
PT-141 can cause transient blood pressure elevation, thereby potentially impairing the efficacy of antihypertensive medications during the dosing period [s8].
Bremelanotide reduces the bioavailability of naltrexone; concomitant use is not recommended per FDA label [s7, s8].
Bremelanotide reduces plasma concentrations of indomethacin; concomitant use is not recommended per FDA label [s7, s8].
A Phase I study investigated co-administration of bremelanotide and ethanol; no clinically relevant additive interaction was identified, though general caution with concurrent use is recommended [s12].
Concurrent injection of PT-141 with PDE-5 inhibitors is not recommended by the International Peptide Society (IPS), as excessive erections and additive hypotension may occur. Temporally staggered administration is considered safer.
Studies
Tier A — High Evidence
Outcome: Erectile function in men with inadequate sildenafil response (IIEF score)
Effect Size: 34% responders (bremelanotide) vs. 9% placebo (significant)
Outcome: Improvement of sexual desire (FSFI-Desire) and personal distress (FSDS-DAO)
Effect Size: Statistically significant improvement vs. placebo; absolute difference moderate
Tier B — Moderate Evidence
Outcome: Mechanism of MC3R/MC4R agonism, erectogenic effect
Effect Size: Qualitative description; no independent effect size
Outcome: Pharmacokinetics, bioavailability, regulatory approval overview
Effect Size: Bioavailability s.c. ~100%; Tmax ~1 h; t½ ~2.7 h
Outcome: Safety and tolerability upon co-administration with ethanol
Effect Size: No clinically relevant additive interaction
Tier C — Low Evidence
Outcome: Melanocortin receptor signaling pathways, dopaminergic and NO activation
Effect Size: Mechanistic description
Community Evidence
Top reported benefits
- Increased sexual desire and libido
- Faster onset of erection in men
- Increased sexual motivation and arousal
- Duration of effect of several hours after a single dose
Top reported issues
- Nausea as a frequent and bothersome side effect
- Unpredictable potency and duration of effect
- Pain during strong erections in combination with PDE-5 inhibitors
- Effort and inconvenience of subcutaneous injection
- High cost of research peptides from unregulated sources
Multiple community reports describe pronounced nausea that overshadows the positive sexual effect [c1, c2]. The need for injection is discussed as a practical and mood-dampening barrier [c3]. A German bodybuilding forum highlighted the legal gray area and procurement risks [c4, c5]. Isolated reports of more severe adverse reactions have been noted, including persistent hyperpigmentation and prolonged priapism-like reactions in men using high doses [c2].
Scientific Sources
- PT-141: a melanocortin agonist for the treatment of sexual dysfunction
Molinoff PB, Shadiack AM, Earle D, et al. (2003). International Journal of Impotence ResearchBPMID:12851303DOI - Europe: Bremelanotide not approved by EMA – review of regulatory status
Gilbert BR (2023). mensreproductivehealth.comCLink - Peptide legal in Deutschland? Rechtslage 2026
Peptide Culture Redaktion (2026). peptide-culture.comCLink - Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants
Spana C, Bhatt DL, Baber U, et al. (2017). Clinical TherapeuticsADOI - Bremelanotid – Wikipedia (Deutsch)
Wikipedia-Autoren (2024). Wikipedia DECLink - Bremelanotid – DocCheck Flexikon
DocCheck Redaktion (2023). DocCheck FlexikonCLink - PharmaWiki – Bremelanotid
PharmaWiki Redaktion (2024). PharmaWiki.chCLink - Bremlanotid, ein Melanocortinrezeptor-Agonist, bessert vermindertes Sexualverlangen bei prämenopausalen Frauen
DGE Blog Redaktion (2019). blog.endokrinologie.netCLink - Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra
Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB (2004). International Journal of Impotence ResearchCDOI - PT-141 (Bremelanotide): Mechanism & Clinical Overview
Newtropin Medical Editorial Team (2024). Newtropin.com (klinische Übersicht)CLink - PT-141 Bremelanotide Research: Complete Guide – Melanocortin Receptor Agonist
Cenexa Labs Editorial Team (2024). Cenexa Labs (wissenschaftliche Übersicht)CLink - Novel Emerging Therapies for Erectile Dysfunction
Yafi FA, Jenkins L, Albersen M, et al. (2018). World Journal of Men's HealthBDOI - Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Simon JA, Kingsberg SA, Portman D, et al. (2019). Obstetrics & GynecologyAPMID:31599840DOI - Bremelanotide: First Approval
Dhillon S (2019). DrugsBPMID:31429064DOI - VYLEESI (bremelanotide injection) – Full Prescribing Information
Palatin Technologies / AMAG Pharmaceuticals (2019). U.S. Food and Drug Administration (FDA)ALink - PT-141 Side Effects and Safety Profile
Peptide Protocol Wiki Editorial Team (2024). Peptide Protocol WikiCLink - Vyleesi (Bremelanotid-Injektion): Anwendungen, Dosierung, Nebenwirkungen, Wechselwirkungen – Swissdocu / Orthopädie Innsbruck
SwissDocu Redaktion (2023). SwissDocu / orthopaedie-innsbruck.atCLink
Community Sources
Storage
Unopened
Refrigerator (2–8 °C); store protected from light.
Opened
Use immediately after opening; single-dose autoinjector – not intended for multiple use.
Notes
The FDA-approved Vyleesi® formulation is supplied as a single-use autoinjector. Research peptides from unregulated sources offer no guaranteed sterility or purity; their storage recommendations may differ [s7].